person · Reporting owner

BENDER LEWIS H

Disclosed activity across 1 company

Tapewire entity: 29478
SEC CIK: 0001238705

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
INTENSITY THERAPEUTICS, INC.INTS · Entity 7853	Director · President and CEO	July 16, 2026	July 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INTENSITY THERAPEUTICS, INC.

Report date July 16, 2026 · Filed July 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2036-07-16	Direct	78,000	Reported balance After 2026-07-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-16 · Grant · Acquired 78,000 · Balance 78,000 F1: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 16, 2026 Filed Jul 20, 2026 20:01 UTC	INTENSITY THERAPEUTICS, INC. INTS · Entity 7853	GrantStock Option (right to buy Common Stock) · Derivative	78,000	$0.00 Strike: $4.90	$0.00	Disclosure SEC source: 0001238705-26-000007 · wk-form4_1784577657.xml · derivative · entry 1 BENDER LEWIS H · CIK 0001238705 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2036-07-16 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026. Read SEC document
March 26, 2026 Filed Mar 30, 2026 21:29 UTC	INTENSITY THERAPEUTICS, INC. INTS · Entity 7853	GrantCommon Stock, $0.0001 Par Value	37,749	$6.11	$230,646.39	Disclosure SEC source: 0001238705-26-000005 · wk-form4_1774901174.xml · nonDerivative · entry 1 BENDER LEWIS H · CIK 0001238705 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,549 F1 · shares: Granted to the Reporting Person as a fully vested stock award under the Issuer's 2021 Stock Incentive Plan in partial satisfaction of the 2025 bonus payment to the Reporting Person in lieu of cash, at the Reporting Person's request. F2 · balance_after: On February 18, 2026, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split. Read SEC document
May 02, 2025 Filed May 6, 2025 20:07 UTC	INTENSITY THERAPEUTICS, INC. INTS · Entity 7853	GrantStock Option (right to buy Common Stock) · Derivative	700,000	$0.00 Strike: $0.57	$0.00	Disclosure SEC source: 0001567264-25-000028 · wk-form4_1746562022.xml · derivative · entry 1 BENDER LEWIS H · CIK 0001238705 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2035-05-02 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025. Read SEC document
March 06, 2024 Filed Mar 7, 2024 23:01 UTC	INTENSITY THERAPEUTICS, INC. INTS · Entity 7853	GrantStock Option (right to buy Common Stock) · Derivative	33,574	$0.00 Strike: $5.19	$0.00	Disclosure SEC source: 0001213900-24-020830 · ownership.xml · derivative · entry 2 BENDER LEWIS H · CIK 0001238705 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,574 Underlying: Common Stock · 33,574 shares Expires 2034-03-06 F2 · derivative.exercise_date: This option vested 100% on March 6, 2024. Read SEC document
March 06, 2024 Filed Mar 7, 2024 23:01 UTC	INTENSITY THERAPEUTICS, INC. INTS · Entity 7853	GrantStock Option (right to buy Common Stock) · Derivative	464,805	$0.00 Strike: $5.19	$0.00	Disclosure SEC source: 0001213900-24-020830 · ownership.xml · derivative · entry 1 BENDER LEWIS H · CIK 0001238705 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,805 Underlying: Common Stock · 464,805 shares Expires 2034-03-06 F1 · derivative.exercise_date: This option will vest, subject to the individual's continued employment with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on March 6, 2024. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.